NCT02065869 - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2020

Study Completion Date

September 7, 2021

Conditions

Acute Lymphoblastic LeukemiaLeukemia, Acute Myeloid (AML), ChildLymphoma, Non-HodgkinMyelodysplastic SyndromePrimary ImmunodeficiencyAnemia, AplasticOsteopetrosisHemoglobinopathiesCytopeniaFanconi AnemiaDiamond Blackfan AnemiaThalassemiaAnemia, Sickle Cell

Interventions

BIOLOGICAL

BPX-501 T cells

1x10E6 cells/kg infused on Day 0

DRUG

Rimiducid

0.4mg/kg administered IV to treat GVHD

Trial Locations (4)

00161

IRCCS Ospedale Pediatrico Bambino Gesù, Roma

NW3 2QG

Royal Free London NHS Foundation Trust, London

WC1N 1EH

Institute of Child Health & Great Ormond Street Hospital, London

NE1 4LP

Great North Children's Hospital, Newcastle upon Tyne